Nuveen Asset Management, LLC Adc Therapeutics Sa Transaction History
Nuveen Asset Management, LLC
- $340 Billion
- Q4 2024
A detailed history of Nuveen Asset Management, LLC transactions in Adc Therapeutics Sa stock. As of the latest transaction made, Nuveen Asset Management, LLC holds 152,047 shares of ADCT stock, worth $447,018. This represents 0.0% of its overall portfolio holdings.
Number of Shares
152,047
Previous 129,058
17.81%
Holding current value
$447,018
Previous $406,000
25.62%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding ADCT
# of Institutions
91Shares Held
67.9MCall Options Held
68.2KPut Options Held
75.8K-
Redmile Group, LLC San Francisco, CA15.7MShares$46.1 Million5.11% of portfolio
-
Prosight Management, LP Dallas, TX10.5MShares$30.8 Million7.6% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct7.76MShares$22.8 Million0.05% of portfolio
-
Orbimed Advisors LLC San Diego, CA5.91MShares$17.4 Million0.57% of portfolio
-
Black Rock Inc. New York, NY3.55MShares$10.5 Million0.0% of portfolio
About ADC Therapeutics SA
- Ticker ADCT
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 77,645,296
- Market Cap $228M
- Description
- ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma;...